Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Lilly

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

with Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.

Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus

Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus February. Rybelsus is the first and so far only oral alternative to injectable GLP-1 agonists such as Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Ozempic (semaglutide) and Victoza ... 2 diabetics than Merck &Co’s oral DPP-4 inhibitor

The impact of COVID-19 on clinical trials

The impact of COVID-19 on clinical trials Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.

Remdesivir closes in on receiving first EU approval for treatment for COVID-19

Remdesivir closes in on receiving first EU approval for treatment for COVID-19 A second NIAID trial – ACTT-2 – is testing the combination of remdesivir with Eli Lilly’s anti-inflammatory JAK inhibitor Olumiant (baricitinib) in patients hospitalised with COVID-19.

Gilead will test inhaled remdesivir in earlier-stage COVID-19

Gilead will test inhaled remdesivir in earlier-stage COVID-19 Combination studies and testing in additional patient groups are at the planning stages, said the CEO, noting that trials of remdesivir with anti-inflammatory drugs – Eli Lilly’s JAK inhibitor Olumiant

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics